相关实验视频
Updated: Jul 6, 2025

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
Published on: April 25, 2022
RNA 瘤疗法:细胞内毛RNA 组合可启动微RNA 触发的抗癌功能
Kunihiko Morihiro1, Shunto Morita1, Naoki Harada1
1Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan.
研究人员开发了一种新型的瘤性RNA发针对 (oHP),可选择性地向并杀死癌细胞. 这种RNA疗法由致癌的microRNA-21激活,作为抗癌剂.
科学领域:
- 生物化学
- 分子生物学
- 抗癌药物
背景情况:
- 对于生物分子来说,RNA疗法具有多样性.
- 长双链RNA (dsRNA) 显示出作为免疫激活抗瘤剂的潜力.
- 目前的dsRNA疗法在癌症选择性和细胞透方面面临挑战.
研究的目的:
- 设计和合成一种新型的瘤性RNA毛针对 (oHP).
- 达到对表达微RNA-21 (miR-21) 的癌细胞的选择性细胞毒性.
- 开发一种由瘤性miRNA触发的积聚型抗癌剂.
主要方法:
- 设计和合成一种热力学转基因稳定的瘤RNA针对 (oHP).
- 由miR-21触发的oHP的催化开放的证明,以形成长时间的dsRNA.
- 在癌细胞和携带瘤的小鼠中对oHP进行体外和体内测试.
主要成果:
- 对具有高miR-21表达的癌细胞具有选择性细胞毒性.
- miR-21触发了oHP的开放,产生了一个长时间的dsRNA.
- 在各种癌症模型中,oHP在miR-21的存在下充当了细胞毒性放大剂.
结论:
- 这项研究引入了使用由瘤性miRNA触发的短RNA分子的第一个积聚型抗癌剂.
- 该oHP显示选择性杀死癌细胞并具有作为RNA治疗药物的潜力.
- 这种方法克服了传统dSRNA抗瘤剂的局限性.
更多相关视频
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
相关概念视频
Experimental RNAi
MicroRNAs
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
piRNA - Piwi-interacting RNAs
lncRNA - Long Non-coding RNAs